by The global India Immuno-Oncology Drugs Market is estimated to be valued at US$ 338.98 Mn or Mn in 2023 and is expected to exhibit a CAGR of 13.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Immuno-oncology drugs work by enhancing the body’s natural defenses (immune system) to fight cancer using checkpoint inhibitors, cancer vaccines, and cell therapies. They stimulate the immune system to work harder or smarter to attack tumors.This has emerged as a promising approach for treating various types of cancer.
Market key trends:
One of the key trends in the India immuno-oncology drugs market is the increasing adoption of combination therapies. Combination therapies involve using two or more drugs together to enhance treatment effectiveness. For example, combining checkpoint inhibitors like anti-PD-1 with anti-CTLA-4 drugs has shown improved clinical outcomes for various cancer types. Research suggests that combining immunotherapies that target different immune checkpoints can produce longer-lasting responses than single-agent immunotherapy. This is expected to drive the demand for combination immunotherapies in the country.
SWOT Analysis
Strength: The India immuno-oncology drugs market is expected to witness high growth due to increasing healthcare expenditure and focus of key players on expanding their presence.
Weakness: High treatment cost of immuno-oncology drugs and lack of awareness about these drugs.
Opportunity: Increasing prevalence of cancer and rising demand for targeted therapy. Growing adoption of monoclonal antibody therapeutics.
Threats: Stringent regulations for drug approval and adverse effects associated with immunotherapy. Patent expiration of blockbuster drugs.
Key Takeaways
The global India Immuno-Oncology Drugs Market Growth is expected to witness high growth, exhibiting CAGR of 13.% over the forecast period, due to increasing prevalence of cancer.
Regional analysis
The India immuno-oncology drugs market is expected to be dominated by the South region over the forecast period owing to presence of supportive healthcare infrastructure and key regional players. The west region is expected to exhibit a considerable growth rate owing to rising healthcare spending.
Key players operating in the India immuno-oncology drugs market are Amgen Inc., F. Hoffmann-La Roche AG., Intas Pharmaceuticals Ltd., AstraZeneca plc, Mylan N.V., Dr. Reddy’s Laboratories, Bristol – Myers Squibb, Merck & Co., Inc., BIOCAD-Biotechnology company, Reliance Life Sciences, Biocon Limited, and Hetero Drugs Limited.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
